Brevan Howard Capital Management
FTH icon

Brevan Howard Capital Management’s Faeth Therapeutics FTH Stock Holding History

Brevan Howard Capital Management’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,333
Closed -$641K – 2548
2026
Q1 		$641K Buy
+20,333
New +$406K 0.01% 1156

Other funds holding FTH

Suvretta Capital Management
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Fairmount Funds Management
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Logos Global Management
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vivo Capital
Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return
Caligan Partners
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return

Brevan Howard Capital Management's FTH Position: Q2 2026 in Review

Brevan Howard Capital Management sold out of Faeth Therapeutics (FTH) in Q2 2026, closing a stake of 20,333 shares — an estimated $641K sold.

Brevan Howard Capital Management first reported a position in FTH in Q1 2026 and held it in 1 quarter. The position peaked at $641K in Q1 2026. 45 funds tracked by Wall St. Rank hold FTH as of Q2 2026.

  • Brevan Howard Capital Management reported no remaining Faeth Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 20,333 Faeth Therapeutics shares in Q2 2026, an estimated $641K.
  • Brevan Howard Capital Management first reported a position in Faeth Therapeutics in Q1 2026 and held it in 1 quarter.
  • Brevan Howard Capital Management's Faeth Therapeutics position peaked at $641K in Q1 2026.
  • 45 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.